Publications

119. Helmers M, Atluri P. Passing needle through stone: A novel surgical technique for porcelain aorta. J Thorac Cardiovasc Surg 2017.

118. Gaffey AC, Chen CW, Chung JJ, Han J, Owens A, Acker MA, Atluri P. Extended distance cardiac allograft can successfully be utilized without impacting long-term survival. J Heart Lung Transplant 2017.

117. Daniel M, Atluri P. Examining the dark recesses of the heart: Technology drives innovation. J Thorac Cardiovasc Surg 2017.

116. Chen CW, Dumon KR, Shaked O, Acker MA, Atluri P, Dempsey DT. Non-cardiac surgery in patients with continuous-flow left ventricular assist devices: a single institutional experience. J Investig Med 2017.

115. Gutsche JT, Ghadimi K, Augoustides JGT, Evans A, Ko H, Weiner M, Raiten J, Lane-Fall M, Gordon E, Atluri P, Milewski R, Horak J, Patel P, Ramakrishna H. The Year in Cardiothoracic Critical Care: Selected Highlights From 2016. J Cardiothorac Vasc Anesth 2017.

114. Chen CW, Sprys MH, Gaffey AC, Chung JJ, Margulies KB, Acker MA, Atluri P. Low ejection fraction in donor hearts is not directly associated with increased recipient mortality. J Heart Lung Transplant 2017.

113. Menachem JN, Golbus JR, Molina M, Mazurek JA, Hornsby N, Atluri P, Fuller S, Birati EY, Kim YY, Goldberg LR, Wald JW. Successful cardiac transplantation outcomes in patients with adult congenital heart disease. Heart 2017.

112. Kilic A, Atluri P. Gone fishing: Looking to catch some answers for differing mortality in the CoreValve High-Risk Trial. J Thorac Cardiovasc Surg 2017.

111. Bartoli CR, Kang J, Zhang D, Howard J, Acker M, Atluri P, Motomura T. Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System. Ann Thorac Surg 2017.

110. Gaffey AC, Chen CW, Hiesinger W, Chung J, Grandin EW, Porrett PM, Jessup ML, Acker MA, Atluri P. Bridge with a left ventricular assist device to simultaneous heart and kidney transplant: review of the united network for organ sharing database. J Card Surg 2017.

109. Han JJ, Sooppan R, Johnson AP, Chen CW, Gaffey AC, Phillips EC, Howard J, Rame JE, Acker MA, Atluri P. Higher Body Mass Index Increases Risk of HeartMate II Pump Thrombosis But Does Not Adversely Affect Long-Term Survival. Circ J 2017.

108. Grandin EW, Zamani P, Mazurek JA, Troutman GS, Birati EY, Vorovich E, Chirinos JA, Tedford RJ, Margulies KB, Atluri P, Rame JE. Right ventricular response to pulsatile load is associated with early right heart failure and mortality after left ventricular assist device. J Heart Lung Transplant 2017.

107. Chung JJ, Arisi MF, Zaman S, Atluri P. Engineering the Future One Cell at a Time: Advancements in Cell-Based Techniques from Novel Three-Dimensional Cell Culture to a Bionic Kidney. ASAIO J 2017.

106. Wang LL, Sloand JN, Gaffey AC, Venkataraman CM, Wang Z, Trubelja A, Hammer DA, Atluri P, Burdick JA. Injectable, Guest-Host Assembled Polyethylenimine Hydrogel for siRNA Delivery. Biomacromolecules 2017.

105. Ibrahim M, Atluri P. Transdifferentiation: A new frontier in cardiovascular cell therapy. J Thorac Cardiovasc Surg 2017.

104. Williams ML, Bavaria JE, Acker MA, Desai ND, Vallabhajosyula P, Hargrove WC, Atluri P, Szeto WY. Valve selection in end stage renal disease: should it always be biological? Ann Thor Surg 2016.

103. Ibrahim M, Kilic A, Atluri P. Left Ventricular Assist Devices and Small Body Surface Area - A Clinical Concern? Circ J 2016.

102. Kilic A, Atluri P. Stapled aortic graft-to-graft anastomoses: Is automation optimization? J Thorac Cardiovasc Surg 2016.

101. Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, Acker MA, Hung JW, Chang HL, Perrault LP, Gillinov AM, Argenziano M, Bagiella E, Overbey JR,  Moquete EG, Gupta LN, Miller MA, Taddei-Peters WC, Jeffries N, Weisel RD, Rose EA, Gammie JS, DeRose JJ, Puskas JD, Dagenais F, Burks SG, Hamamsy IE, Milano CA, Atluri P, Voisine P, O’Gara PT,  Gelijns AC. Two year outcomes following surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2016.

100. Kang J, Zhang DM, Restle DJ, Kallel F, Acker MA, Atluri P, Bartoli CR. Reduced continuous-flow left ventricular assist device speed does not decrease von willebrand factor degradation. J Thor Cardiovasc Surg 2016.

99. Vallabhajosyula P, Kramer M, Lazar S, McCarthy F, Rame E, Wald J, Szeto W, Williams M, Atluri P, Desai N, Acker M. Lower-extremity complications with femoral extracorporeal life support. J Thorac Cardiovasc Surg 2016.

98. McCarthy FH, McDermott KM, Spragan D, Hoedt A, Kini V, Atluri P, Gaffey A, Szeto WY, Acker MA, Desai ND. Unconventional Volume-Outcome Associations in Adult Extracorporeal Membrane Oxygenation in the United States. Ann Thorac Surg 2016.

97. Heatley G, Sood P, Goldstein D, Uriel N, Cleveland J, Middlebrook D, Mehra MR. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung Transplant 2016.

96. Hiesinger W, Atluri P. Hybrid coronary revascularization: ready for prime time, but who should star? J Thorac Cardiovasc Surg 2016.

95. Chen CW, Atluri P. Nonfunctional pacemaker leads: To remove or not to remove, that is the multifactorial question. J Thorac Cardiovasc Surg 2016.

94. Gaffey AC, Hung G, Howard J, Doll S, Thomasson AM, Chen CW, Goldberg LR, Blumberg EA, Acker MA, Stone F, Atluri P. Transplantation for center for disease control “high risk” donor hearts: Implications for infection. J Thorac Cardiovasc Surg 2016.

93. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016.

92. Kang J, Zhang DM, Restle DJ, Kallel F, Acker MA, Atluri P, Bartoli CR. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation. J Thorac Cardiovasc Surg 2016.

91. Birati EY, Mathelier H, Molina M, Hanff TC, Mazurek JA, Atluri P, Acker MA, Rame JE, Margulies KB, Goldberg LR, Jessup M.Comparison of Causes of Death After Heart Transplantation in Patients With Left Ventricular Ejection Fractions ≤35% Versus >35. Am J Cardiol 2016.

90. Gaffey AC, Doll SL, Thomasson AM, Venkataraman C, Chen CW, Goldberg LR, Blumberg EA, Acker MA, Stone F, Atluri P. Transplantation of "high-risk" donor hearts: Implications for infection. J Thorac Cardiovasc Surg 2016.

89. Gaffey AC, Cucchiara AJ, Hung G, Goldberg LR, Blumberg EA, Acker MA, Atluri P. Transplantation of center for disease control “high risk” donor hearts does not adversely impact long term outcomes in adults. J Card Failure 2016.

88. Han J, Gaffey AC, Soopan R, Hung G, Venkataraman C, Phillips E, Howard J, Acker MA, McLean R, Atluri P. Heartmate II left ventricular assist device geometry on chest radiograph may be a dynamic marker of remodeling. ASAIO J 2016.

87. Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, Hung YP, Voisine P, Dagenais F, Gillinov AM, Thourani V, Argenziano M, Gammie JS, Mack M, Demers P, Atluri P, Rose EA, O’Sullivan K, Williams DL, Bagiella E, Michler RE, Weisel RD, Miller MA, Geller NL, Taddei-Peters WC, Smith PK, Moquete E, Overbey JR, Kron IL, O’Gara PT, Acker MA. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 2016;374:344-353.

86. Atluri P, Stetson R, Gaffey AC, Szeto WY, Acker MA, Hargrove WC. Minimally invasive mitral valve surgery is associated with equivalent cost and shorter hospital length of stay when compared to traditional sternotomy. J Thorac Cardiovasc Surg 2016;151:385-388.

85. Sooppan RV, Paulsen SJ, Han J, Ta HA, Dinh P, Gaffey AC, Venkataraman C, Trubelja AS, Hung G, Miller JS, Atluri P. In vivo implant and microvascular perfusion of a 3D printed internally vascularized construct.  Tissue Eng Part C 2016;22:1-7.

84. McCarthy FH, Kobrin D, Rame JE, Groeneveld PW, McDermott KM, Atluri P, Acker MA, Desai ND. Increasing frequency of left ventricular assist device exchange in the United States: Is there cause for concern? Ann Thor Surg 2015; 100:1660-1664.

83. Gaffey AC, Atluri P. Post-left ventricular assist device support right ventricular failure: can it be predicted preoperatively and should it be a contraindication to implantation? J Thorac Cardiovasc Surg 2015; 150:1659-1660.

82. Hiesinger W, Atluri P. Building a better bridge: Remodeling, recovery, and a better understanding of the biologic foundation of mechanical circulatory support. J Thorac Cardiovasc Surg 2015; 150:1342-1343.

81. McCarthy FH, McDermott KM, Kini V, Gutsche JT, Wald JW, Xie D, Szeto WY, Bermudex CA, Atluri P, Acker MA, Desai ND. Trends in U.S. extracorporeal membrane oxygenation use and outcomes: 2002-2012. Sem Thorac Cardiovasc Surg 2015;27:81-88.

80. Kilic A, Acker MA, Atluri P. Dealing With Surgical Left Ventricular Assist Device Complications. J Thor Dis 2015; 7:2158-2164.

79. Sultan I, Atluri P. Total endovascular arch replacement: Are we there yet? Are we there yet? J Thor Cardiovasc Surg 2015.

78. Bartoli CR, Atluri P. Do patients with continuous flow devices benefit from induced pulsatility or are we just spinning our wheels? J Thorac Cardiovasc Surg 2015; 150:945-946.

77. Bartoli CR, Kang J, Restle DJ, Zhang DM, Shabahang C, Acker MA, Atluri P. Inhibition of ADAMTS-13 by doxycycline reduces von Willebrand factor degradation during supraphysiologic shear stress: therapeutic implications of left ventricular assist device associated bleeding. JACC Heart Fail 2015; 11:860-869.

76. Gaffey AC, Atluri P. Post-LVAD right ventricular failure: can it be predicated pre-operatively and should it be a contraindication to implant? J Thorac Cardiovasc Surg 2015; 6:1659-60.

75. Hiraoka A, Cohen JE, Shudo Y, MacArthur JW, Howard JL, Fairman AS, Atluri P, Kirkpatrick JN, Woo YJ. Evaluation of late aortic insufficiency with continuous flow left ventricular assist device. Eur J Cardiothorac Surg 2015; 48: 400-406.

74. Birati EY, Quiaoit Y, Wald J, Kirkpatrick JN, Goldberg LR, Atluri P, Margulies KB, Rame JE. Ventricular assist device thrombosis: a wide spectrum of clinical presentation. J Heart Lung Transp 2015; 34: 613-615.

73. Shudo Y, Cohen JE, MacArthur JW, Goldstone AB, Hiraoka A, Howard J,  Fairman, AS, Patel J, Edwards BE, Atluri P, Woo YJ. Non-resectional leaflet remodeling mitral valve repair preserves leaflet mobility: a quantitative echocardiographic analysis of mitral valve configuration. Int J Cardiol 2015; 186: 16-18.

72. Restle DJ, Zhang DM, Hung G, Howard JL, Kallel F, Acker MA, Atluri P, Bartoli CR. Preclinical models for translational investigations of lvad-associated von willebrand factor degradation Artif Organs 2015; 39:569-575.

71. Atluri P, Woo YJ. Combined Heart-Liver Transplantation Experience and Improved Organ Utilization. Ann Thor Surg 2015; 99:1489.

70. Goldstone AB, Cohen JE, Howard JL, Edwards BB, Acker AL, Hiesinger W, MacArthur JW, Atluri P, Woo YJ. A “repair-first” strategy for degenerative mitral valve disease safely minimizes unnecessary replacement. Ann Thor Surg 2015; 99:1983-1990.

69. Gaffey AC, Phillips EC, Howard J, Hung G, Han J, Emery RJ, Goldberg L, Acker MA, Woo YJ, Atluri P. Prior sternotomy and ventricular assist device implant do not adversely impact survival or allograft function following heart transplant. Ann Thor Surg 2015; 100:542-549.

68. Kornfield NZ, Horak J, Gibbs RM, Weiss SJ, Atluri P, Augostides JG, Gutsche JT, Sidebotham D. Extracorporeal membrane oxygenation as a bridge to clinical recovery in life-threatening autoimmune acute respiratory distress syndrome. J Cardiothor Vasc Anesth 2015; 29:221-228.

67. Bartoli CR, Restle D, Zhang D, Acker MA, Atluri P. von Willebrand Factor Degradation with an LVAD Occurs via Two Distinct Mechanisms:Mechanical Demolition and Enzymatic Cleavage. J Thor Cardiovasc Surg 2015; 149:281-289.

66. Vernick W, Szeto WY, LI RJ, Atluri P, Augostides JG, Kukafka JD, Patel PA, Gutsche JT. The utility of atrioventricular pacing via a pulmonary artery catheter during transcatheter aortic valve replacement. J Cardiothor Vasc Anesth 2015.

65. Gaffey AC, Chen MH, Trubelja A, Venkataraman C, Dinh PV, Chen CW, Schultz S, Lee J, Sehgal CM, Burdick JA, Atluri P. Injectable shear-thinning hydrogels to deliver endothelial progenitor cells, reduce ventricular strain, and dynamic stiffness to stabilize cardiac function following ischemic injury. Circ Heart Failure 2015.

64. Gaffey AC, Chen MH, Venkataraman C, Trubelja AS, Rodell CB, Dinh PV, Hung G, MacArthur JW, Soopan RV, Burdick JA, Atluri P. Injectable shear-thinning hydrogels to deliver endothelial progenitor cells to enhance cell engraftment and improve ischemic myocardium. J Thorac Cardiovasc Surg 2015; 150:1268-1277.

63. DeLong MR, Hughes DB, Gaca JG, Fischer J, Bond JE, Hargrove WC, Atluri P, Levin LS, Erdmann D. Sternal talon offers a solution for secondary sternum osteosynthesis in patients with nonunion. Ann Thor Surg 2014; 98:1579-1583.

62. Goldstone AB, Howard JL, Cohen JE, MacArthur JW, Atluri P, Kirkpatrick JN, Woo YJ. Natural history of coexistent tricuspid regurgitation in patients with degenerative mitral valve disease:implications for future guidelines. J Thor Cardiovasc Surg 2014; 148:1090-1097.

61. Atluri P, Goldstone AB, Fox Jeanne, Szeto WY, Hargrove WC. Port access cardiac surgery can be safely performed utilizing either endoaortic balloon or chitwood clamp. Ann Thor Surg 2014; 98:1579-1583.

60. Atluri P, Gaffey A, Howard J, Phillips E, Goldstone AB, Hornsby N, MacArthur JW, Cohen JE, Gutsche J, Woo YJ. Combined heart and liver transplantation can be safely performed with excellent short- and long-term results. Ann Thor Surg 2014; 98:858-862.

59. Rame E, Atluri P, Acker MA. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014; 370: 1466-1467.

58. MacArthur JW, Cohen JE, McGarvey J, Shudo Y, Patel JB, Trubelja A, Fairman A, Edwards BB, Hung G, Goldstone AB, Hiesinger W, Atluri P, Wilensky RL, Pilla J, Gorman JH, Gorman RC, Woo YJ. Preclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1-alpha analogue in a translational ovine myocardial infarction model. Circ Res 2014; 114:650-659.

57. Cohen JE, Purcell BP, MacArthur JW, Mu A, Shudo Y, Patel JB, Brusalis CM, Trubelja A, Fairman AS, Edwards BB, Davis MS, Hung G, Hiesinger W, Atluri P, Margulies KB, Burdick JA, Woo YJ. A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy. Circ Heart Fail 2014; 4:619-626.

56. Trubelja A, MacArthur JW Jr, Sarver JJ, Cohen JE, Hung G, Shudo Y, Fairman AS, Patel JB, Edwards BB, Damrauer SM, Hiesinger W, Atluri P, Woo YJ. Bioengineered sdf-1a analogue delivered as an angiogenic therapy significantly restores viscoelastic material properties of infarcted cardiac muscle. J Biomech Eng 2014: 138.

55. Atluri P, Miller JS, Emery RJ, Hung G, Trubelja A, Cohen JE, Lloyd K, Han J, Gaffey AC, Patel JB, MacArthur JW, Chen CS, Woo YJ. Tissue engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function. J Thor Cardiovasc Surg 2014; 148: 1090-1097.

54. Gutsche JT, Kornfield ZN, Speck RM, Patel PA, Atluri P, Augostides YG. Impact of guideline implementation on transfusion practices in a surgical intensive care unit. J Cardiothor Vasc Anest. 2013; 28:770-775.

53. Atluri P, Fairman AS, MacArthur JW, Howard JL, Yang E, Shudo Y, Hiesinger W, Woo YJ. Continuous flow left ventricular assist device implant significantly improves pulmonary hypertension, right ventricular contractility and tricuspid valve competence. J Card Surg. 2013; 28:770-775.

52. Atluri P, Woo YJ, Goldstone AB, Fox J, Acker MA, Szeto WY, Hargrove WC. Minimally invasive mitral valve surgery can be performed with optimal outcomes in the presence of left ventricular dysfunction. Ann Thor Surg. 2013; 96:1596-1601.

51. MacArthur JW, Cohen JE, Goldstone AB, Fairman AS, Edwards BB, Hornick MA, Atluri P, Woo YJ. Nonresectional single-suture leaflet remodeling for degenerative mitral regurgitation facilitates minimally invasive mitral valve repair. Ann Thor Surg. 2013; 96:1603-1606.

50. Atluri P, Dymond DJ, Woo YJ. Continuous flow left ventricular assist device implantation in the presence of a hostile ventricle. J Thor Cardiovasc Surg. 2013; 146: 981-982.

49. Atluri P, Trubelja A, Fairman AS, Hsiao P, MacArthur JW, Cohen JE, Shudo Y, Frederick JR, Woo YJ. Normalization of post-infarct biomechanics utilizing a novel tissue engineered angiogenic construct. Circulation. 2013; 128: S95-104

48. Gutsche J, Atluri P, Augostides JG. Treatment of ventricular assist-device-associated gastrointestinal bleeding with hormonal therapy. J Cardiothor Vasc Anesth. 2013; 27; 939-943.

47. Atluri P, Goldstone AB, Kobrin DM, Cohen JE, MacArthur JW, Howard JL, Jessup ML, Rame JE, Acker MA, Woo YJ. Ventricular assist device implant in the elderly is associated with increased, but respectable risk. Ann Thor Surg. 2013; 96:141-147.

46. Atluri P, Goldstone AB, Fairman AS, MacArthur JW, Shudo Y, Cohen JE, Acker AL, Hiesinger W, Howard JL, Acker MA, Woo YJ. Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thor Surg. 2013; 96: 857-864.

45. Vernick W, Atluri P. Robotic and minimally invasive cardiac surgery. Anesthes Clin 2013; 31: 299-320.

44. Goldstone  AB, Atluri P, Szeto WY, Trubelja A, Howard JL, MacArthur JW, Gorman RC,  Gorman JH, Pochettino A, Bavaria JE, Acker MA, Hargrove WC, Woo YJ. Propensity score adjusted comparison of minimally invasive versus sternotomy approaches to isolated mitral valve repair. J Thor Cardiovasc Surg. 2013; 145: 748-758.

43. Atluri P, Acker MA. Diastolic ventricular support with cardiac support devices: an alternative approach to prevent adverse ventricular remodeling. Heart Failure Rev. 2013; 18:55-63.

42. Atluri P, Ullery BW, MacArthur JW, Goldstone AB, Fairman AS, Hiesinger W, Acker MA, Woo YJ. Rapid onset of fulminant myocarditis portends a favorable prognosis and ability to bridge mechanical support to recovery. Eur J Cardiothor Surg. 2013; 43: 379-382.

41. Hiesinger W, Cohen JE, Atluri P. Therapeutic potential of Rb phosphorylation in atherosclerosis. Cell Cycle. 2013; 13:352.

40. MacArthur JW. Purcell B, Shudo Y, Cohen JE, Fairman AS, Trubelja A, Patel J, Hsaio P, Yang E, Lloyd K, Hiesinger W, Atluri P, Woo YJ. Sustained release of engineered stromal cell-derived factor 1-alpha from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function following myocardial infarction. Circulation. 2013; 128:S79-86.

39. Shudo Y, Cohen JE, MacArthur JW, Atluri P, Hsaio P, Yang E, Fairman AS, Trubelja A, Patel J, Miyagawa S, Sawa Y, Woo YJ. Spacially-oriented, temporally-sequential smc-epc bi-level cell-sheet neovascularizes ischemic myocardium. Circulation. 2013; 128: S59-68.

38. MacArthur JW, Trubelja A, Shudo Y, Hsiao P, Fairman A, Yang E, Hiesinger W, Atluri P, Woo YJ.  Mathematically-engineered stromal cell-derived factor 1alpha stem cell cytokine analogue enhances mechanical properties of infarcted myocardium. J Thorac Cardiovasc Surg. 2013; 145:278-284.

37. Atluri P, Acker MA. Mitral valve surgery for dilated cardiomyopathy - current status and future role. Sem Thor Cardiovasc Surg. 2012 Spring; 24:51-8.

36. Atluri P, MacArthur JW. A novel strategy to improve end organ function with pulsatile cardiopulmonary bypass. Circ J. 2012; 76: 1087-1088.

35. Hiesinger W, Brukman MJ, McCormick RC, Fitzpatrick JR, Frederick JR, Yang EC, Muenzer JR, Marotta NA, Berry MF, Atluri P, Woo YJ. Myocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor-1α angiogenic therapy for acute myocardial infarction in a murine model. J Thoracic and Cardiovasc Surg. 2012; 143:962-966.

34. Atluri P, Acker MA, Jessup ML. The next decade in mechanical assist - advances that will help the patient and the doctor. Current Opin Cardiol 2011; 26:256-260.

33. Atluri P, Woo YJ. Minimally invasive, robotic mitral valve surgery: equivalent technical outcomes with improved morbidity. Expert Rev Medical Devices 2011; 8; 115-120.

32. Hiesinger W, Perez-Aguilar JM, Atluri P, Marotta N, Frederick JR, Fitzpatrick JR, McCormick RC, Muenzer JR, Levit RD, Yuan LJ, MacArthur JW, Saven JG, Woo YJ. Computational protein design to re-engineer stromal cell-derived factor-1α (SDF) generates a supra-efficient angiogenic polypeptide analog. Circulation 2011; 124:S18-26.

31. Hiesinger W, Vinogradov S, Atluri P, Fitzpatrick JR, Frederick J, Levit R, McCormick R, Muenzer J, Yang E, Marotta N, MacArthur J, Wilson D, Woo YJ. Oxygen-dependent quenching of phosphorescence used to characterize improved myocardial oxygenation resulting from targeted endothelial progenitor cell therapy. J Appl Physio.2011 May;110(5):1460-1465

30. Atluri P. Careful echocardiographic analysis of right ventricular function as a long-term prognostic variable in systolic heart failure. Circ J. 2011; 75: 2054-2055.

29. Atluri P, Acker MA. Pulsatile LVADs: What is the role in the modern era? Semin Thor Cardiovasc Surg 2010; 22; 106-108.

28. Woo YJ, Atluri P. Angiogenesis and surgical or endovascular enhancement of non-coronary collateral circulation:  a new research field. J Thor Cardiovasc Surg. 2010; 139:1676-1677.

27. Hiesinger W, Frederick JR, Atluri P, McCormick RC, Marotta N, Muenzer JR, Woo YJ. Spliced stromal cell-derived factor-1α analog stimulates endothelial progenitor cell migration and improves cardiac function in a dose-dependent manner after myocardial infarction. J Thor Cardiovasc Surg 2010; 140; 1174-1180.

26. Frederick JR, Fitzpatrick JR, McCormick RC, Harris DA, Kim AY, Muenzer JR, Marotta N, Smith MJ, Cohen JE, Hiesinger W, Atluri P, Woo YJ. Stromal cell-derived factor-1α activation of tissue engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis. Circulation 2010; 122; S107-117.

25. Atluri P. Myocardial transfection of adeno-hypoxia inducible factor-1α, a novel strategy to potentiate vasculogenesis in ischemic myocardium.  Circ J. 2010; 74:846-847.

24. Atluri P, Panlilio CM, Liao GP, Hiesinger W, Harris DA, McCormick RC, Cohen JE, Jin T, Feng W, Levit RD, Dong N, Woo YJ. Acute myocardial rescue with endogenous endothelial progenitor cell therapy. Heart, Lung, Circulation 2010; 11; 644-654.

23. Augostides JGT, Atluri P. Progress in mitral valve disease: understanding the revolution. J Cardiovasc Anesth 2009; 23: 916-923.

22. Atluri P, Kozin ED, Hiesinger W, Woo YJ. Off-pump, minimally invasive, and robotic coronary revascularization yield improved outcomes over traditional on-pump CABG. Int J Med Robot 2009; 5: 1-12.

21. Atluri P, Hiesinger W, Gorman RC, Pochettino A, Jessup M, Acker MA, Morris RJ, Woo YJ. Cardiac retransplantation is an efficacious therapy for primary cardiac allograft failure. J Cardiothor Surg 2008; 3:26-30.

20. Atluri P, Woo YJ. Pro-angiogenic cytokines as cardiovascular therapeutics: assessing the potential. BioDrugs 2008; 22: 209-222.

19. Atluri P, Panlilio CM, Liao GP, Suarez EE, McCormick RC, Hiesinger W, Cohen JE, Smith MJ, Patel AB, Feng W, Woo YJ. Transmyocardial revascularization enhances myocardial vasculogenesis and hemodynamic function. J Thor Cardiovasc Surg 2008; 135; 2:283-291.

18. Atluri P, Morine KJ, Liao G, Panlilio CM, Berry MF, Hsu VM, Cohen J, Smith M, Suarez E, Sweeney HL, Woo YJ. Ischemic heart failure enhances endogenous myocardial apelin ligand and apj receptor expression. Cell & Mol Bio Lett 2007; 12:127-138.

17. Atluri P, Woo YJ. High risk ascending aortic aneurysm repair resulting from giant cell aortitis. Asian Cardiovasc Thor Ann 2007; 15: 252-254.

16. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Suarez EE, Atluri P, Chaudhry HW.  Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin a2. J Thor Cardiovasc Surg 2007; 133; 4:927-933.

15. Woo YJ, Rodriguez E, Atluri P, Chitwood WR. Minimally-invasive, robotic, and off-pump mitral valve surgery. Seminars Thor Cardiovasc Surg 2006; 18: 139-47.

14. Hsu VM, Atluri P, Keane M, Woo YJ. Minimally invasive aortic valve papillary fibroelastoma resection. Interactive Cardio Thor Surg. 2006; 5: 779-781.

13. Atluri P, Neligan PJ, Acker MA, Bensall DL, Horak J. Prone Positioning to Treat Acute Severe Pulmonary Edema in the Post-Cardiac Surgical Patient. Heart Surg Forum. 2006; 9: 762-4.

12. Atluri P, Morine KJ, Liao G, Panlilio CM, Berry MF, Hsu VM, Cohen J, Smith M, Suarez E, Sweeney HL, Woo YJ. Ischemic heart failure enhances endogenous myocardial apelin ligand and apj receptor expression. Cell & Mol Bio Lett 2007; 12:127-138.

11. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Hsu VM, Cohen JE, Chaudhry HW.  Therapeutic Delivery of Cyclin A2 Induces Myocardial Regeneration and Enhances Cardiac Function in Ischemic Heart Failure. Circulation. 2006; 114(1 Suppl): I206-13.

10. Kolakowski S, Berry MF, Grand TJ, Fisher O, Moise MA, Cohen JE, Hsu V, Atluri P, Woo YJ. Placental growth factor provides a novel local angiogenic therapy for ischemic cardiomyopathy. J Card Surg. 2006; 21: 559-564.

9. Cohen JE, Atluri P, Taylor MD, Grand TJ, Liao GP, Panlilio CM, Suarez EE, Zentko SE, Hsu VM, Berry MF, Smith MJ, Gardner TJ, Sweeney HL, Woo YJ. Fructose 1,6-diphosphate Administration Attenuates Post-Ischemic Ventricular Dysfunction. J Heart Lung Circ. 2006; 2: 119-123.

8. Atluri P, Liao GP, Panlilio CM, Hsu VM, Leskowitz MJ, Morine KJ, Cohen JE, Berry MF, Suarez EE, Murphy DA, Lee WMF, Gardner TJ, Sweeney HL, Woo YJ. Neovasculogenic therapy with granulocyte-monocyte colony stimulating factor and stromal cell derived factor-1α augments perfusion, reverses ischemia and preserves cardiomyocyte viability in ischemic cardiomyopathy. Ann Thor Surg. 2006; 81: 1728-1736.

7. Woo YJ, Atluri P, Grand TJ, Hsu V, Cheung A. Active thermoregulation improves off-pump coronary artery bypass grafting outcomes.  Asian Cardiovasc Thor Ann 2005; 13:157-160.

6. Atluri P, Raper S. Factor V leiden and post-operative deep vein thrombosis in patients undergoing open roux-en-y gastric bypass surgery. Obes Surg. 2005; 15:561-564.

5. Woo YJ, Grand TJ, Zentko S, Cohen JE, Hsu V, Atluri P, Berry MF, Taylor MD, Moise MA, Burdick J, Fisher O, Kolakowski S.  Creatine phosphate administration preserves myocardial function in a model of off-pump coronary revascularization.  J Cardiovasc Surg. 2005; 46:297-303.

4. Woo YJ, Grand T, Berry MF, Atluri P, Moise A, Hsu V, Cohen J, Fisher O, Burdick J, Taylor M, Zentko S, Liao G, Smith M, Kolakowski S, Jayasankar V, Gardner TJ, Sweeney HL. Stromal-cell derived factor and granulocyte monocyte-colony stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thor Cardiovasc Surg. 2005; 130: 321-329.

3. Woo YJ, Atluri P, Grand TJ, Hsu V, Gardner TJ. Should protamine dosing formulas be recalculated for off-pump coronary artery bypass grafting?  Heart Surg Forum. 2003; 7: 42-44.

2. Schneider AS, Atluri P, Shen Q, Barnes W, Mah SJ, Stadfelt D, Goderie SK, Temple S, and  Fleck MW. Functional nicotinic acetylcholine receptor expression on stem and progenitor cells of the early embryonic nervous system. Ann. N.Y. Acad. Sci. 2002;971: 135-138.

1. Atluri P, Fleck MW, Shen Q, Mah SJ, Stadfelt D, Barnes W, Goderie S, Temple S, and Schneider AS. Functional nicotinic acetylcholine receptor expression in stem and progenitor cells of the early embryonic mouse cerebral cortex. Developmental Biology 2001; 240: 143-156.